Medical technology company Becton, Dickinson and Company (BD) has introduced a new family of reagents in a bid to reduce the limits of flow cytometry and expedite the development of drugs for diseases.
The BD Horizon RealYellow 586 Reagents are developed leveraging a novel BD dye technology and artificial intelligence (AI) guidance to provide researchers with deeper insights when compared to traditional fluorochromes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to a BD statement, the launch also marks the first fluorochrome in a series from the BD Horizon RealYellow and RealBlue Reagents product family.
Flow cytometry is a technology that enables researchers to identify and assess the characteristics of single cells.
The technique allows the in-depth study of cells to gain improved understanding of the immune system as well as facilitate the discovery of new biomarkers and treatments.
Fluorochromes, or fluorescent dyes, are a key component in such studies. These photoreactive chemical compounds are excited by laser light and help in the identification of key traits in a cell.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe newly introduced BD Horizon RealYellow 586 Reagents are also optimised for spectral flow cytometry, which allows the measurement of additional characteristics from a single sample.
The company expects that the reagents will help researchers conduct high-dimensional research.
BD biosciences research and clinical solutions vice-president and general manager Steve Conly said: “By overcoming this longstanding limitation in flow cytometry, scientists will now be able to more accurately and confidently study cells of interest, which can streamline discovery research and help unlock potential therapies for disease in a broad range of fields, including virology and oncology.
“With BD Horizon RealYellow and RealBlue Reagents, BD demonstrates its continued leadership in the exciting field of spectral flow cytometry. The new reagents will complement future products that leverage BD CellView Image Technology, our new technology that adds fluorescence imaging and image-based decisioning to sort individual cells at high speed based on the visual details of each cell, to empower researchers with a truly unique solution for cutting-edge flow cytometry.”
Currently, BD Horizon RealYellow 586 Reagents are available globally through online channels and local sales representatives.
Earlier in the year, BD entered a partnership to incorporate the BD Veritor At-Home Covid-19 Test directly into ReturnSafe’s testing management platform.
